tradingkey.logo

Evoke Pharma Inc

EVOK
11.000USD
0.0000.00%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
18.95MMarktkapitalisierung
VerlustKGV TTM

Evoke Pharma Inc

11.000
0.0000.00%

mehr Informationen über Evoke Pharma Inc Unternehmen

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.

Evoke Pharma Inc Informationen

BörsenkürzelEVOK
Name des UnternehmensEvoke Pharma Inc
IPO-datumSep 25, 2013
CEOD'Onofrio (Matthew J)
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeSep 25
Addresse420 Stevens Avenue
StadtSOLANA BEACH
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92075
Telefon18583451494
Websitehttps://evokepharma.com/
BörsenkürzelEVOK
IPO-datumSep 25, 2013
CEOD'Onofrio (Matthew J)

Führungskräfte von Evoke Pharma Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+1318.00%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-1.00%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
--
-27.00%
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
--
-133.00%
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Mr. Mark A. Kowieski
Mr. Mark A. Kowieski
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+1318.00%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-1.00%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
--
-27.00%
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--

Umsatzaufteilung

FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Wed, Feb 4
Aktualisiert: Wed, Feb 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
DRW Securities, LLC
1.38%
Two Sigma Investments, LP
0.61%
D'Onofrio (Matthew J)
0.57%
Andere
79.48%
Aktionäre
Aktionäre
Anteil
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
DRW Securities, LLC
1.38%
Two Sigma Investments, LP
0.61%
D'Onofrio (Matthew J)
0.57%
Andere
79.48%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
10.59%
Investment Advisor
10.08%
Hedge Fund
0.61%
Research Firm
0.01%
Andere
78.71%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
25
502.38K
22.98%
--
2025Q3
26
502.38K
25.40%
+260.79K
2025Q2
25
242.44K
26.58%
-10.18K
2025Q1
28
252.99K
24.26%
-109.24K
2024Q4
30
218.46K
24.86%
-81.81K
2024Q3
31
208.32K
29.69%
-54.34K
2024Q2
31
262.66K
432.25%
-959.00
2024Q1
39
263.62K
30.12%
+47.85K
2023Q4
36
5.70K
3.76%
+99.00
2023Q3
40
5.65K
7.83%
+642.00
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Klein (Roger M.)
163.00K
9.46%
+163.00K
--
Nov 04, 2025
Bleichroeder LP
146.40K
8.5%
+77.64K
+112.94%
Sep 30, 2025
DRW Securities, LLC
23.74K
1.38%
+23.74K
--
Sep 30, 2025
Two Sigma Investments, LP
10.44K
0.61%
+10.44K
--
Sep 30, 2025
D'Onofrio (Matthew J)
9.82K
0.57%
+1.32K
+15.50%
Mar 24, 2025
Kowieski (Mark A.)
4.92K
0.29%
+4.92K
--
Mar 24, 2025
Osaic Holdings, Inc.
3.01K
0.17%
+3.01K
--
Sep 30, 2025
Gonyer (David A)
2.36K
0.14%
-1.00
-0.04%
Mar 24, 2025
Garner (Cam L)
2.33K
0.14%
-1.00
-0.04%
Mar 24, 2025
Northwestern Mutual Capital, LLC
272.00
0.02%
+272.00
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
KeyAI